HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

Core Viewpoint - HOOKIPA Pharma Inc. is in the process of a potential all-share acquisition of Poolbeg Pharma plc, with relevant U.K. disclosure requirements highlighted for shareholders [2][3][8]. Group 1: Acquisition Details - The acquisition was announced on January 2, 2025, and is subject to U.K. City Code on Takeovers and Mergers [2][3]. - Rule 8.3 of the Takeover Code mandates disclosures for shareholders holding 1% or more of relevant securities during the offer period [3]. - Relevant securities include HOOKIPA's common stock, Class A common stock, and various series of convertible preferred stock [3]. Group 2: Company Overview - HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for cancer and serious infectious diseases [5]. - The company utilizes a proprietary arenavirus platform to induce CD8+ T cells and antibodies targeting various cancers, including HPV16+ and KRAS mutated cancers [5]. - HOOKIPA has partnered with Gilead Sciences to develop therapies aimed at functional cures for hepatitis B and HIV-1 [5].